According to the Merck manual which can be found here:
http://www.merck.com/mmpe/sec14/ch169/ch169b.html
Live-microbial vaccines should not be given simultaneously with blood, plasma, or immune globulin, which can interfere with development of desired antibodies; ideally, such vaccines should be given 2 wk before or 6 to 12 wk after the immune globulins.
Immunocompromised patients should not receive live-virus vaccines, which could provoke severe or fatal infections.
Immunocompromised patients should not receive live-virus vaccines, which could provoke severe or fatal infections. In patients receiving short-term (ie, < 14 days) immunosuppressive therapy (eg, corticosteroids, antimetabolites, alkylating compounds, radiation), live-virus vaccines should be withheld until after treatment.
HIB vaccine: Any anaphylactic shock to the vaccine or it's components.
Hepatitis A vaccine: Any known hypersensitivity to the vaccine.
Hepatitis B vaccine: Sensitivity to yeast.
HPV vaccine: Pregnancy and anaphylactic shock to previous dose.
Inactivated flu vaccine: high fever and allergy to egg.
Live flu vaccine spray: Previous history of Guillain-Barre Syndrome/hemoglobinopathies (blood disorders)/immuno-suppression/cardiorespiratory disorders (heart and lung complaints)/pregnancy/asthma/aspirin therapy.
IMPORTANT (VAN UK'S EMPHASIS): Live flu vaccine mist is not suitable for you if you are pregnant or have asthma or have taken aspirin.
MMR Vaccine: pregnancy/immuno-suppression/anaphylactic shock to previous dose/active TB infection/allergy to gelatine/recent treatment with immune globulin (IG).
Meningococcal vaccine: Sensitivity to thimerosal (mercury)/sensitivity to latex/history of Guillain-Barre Syndrome.
Pneumonia vaccine: Pregnancy.
DT vaccine: History of severe reaction to vaccine.
Varicella: Pregnancy/immuno-suppression/treatment with immune globulin (IG)/blood transfusion in the last 5 months/allergic reactions to neomycin or gelatine/active TB/febrile infection.
Adverse effects: Adverse effects are rare and are mostly attributable to the pertussis component. They include encephalopathy within 7 days; a seizure, with or without fever, within 3 days; persistent, severe, inconsolable screaming or crying for ≥ 3 h; collapse or shock within 48 h; temperature of ≥ 40.5° C, unexplained by another cause, within 48 h; and immediate severe or anaphylactic reaction to the vaccine. These reactions contraindicate further use of pertussis vaccine; combined diphtheria and tetanus vaccine is available without the pertussis component.
Mild adverse effects include redness, swelling, and soreness at the injection site.
Adverse effects: Adverse effects are very rare. They include anaphylactic reactions, Guillain-Barré syndrome, and brachial neuritis. Mild effects include redness, swelling, and soreness at the injection site.
Merck State:
Adverse effects: No serious adverse effects have been reported. Mild effects include redness, swelling, and tenderness at the injection site.
But this is untrue as there have been more than 9000 adverse events reported to the FDA's Vaccine Adverse Events Reporting System including 27 deaths.
Adverse effects: Rarely, TIV has adverse effects, such as Guillain-Barré syndrome, anaphylactic reactions, soreness at the injection site, and fever. Adverse effects of LAIV are unusual; they include possible triggering of asthma and transmission of the virus to unimmunized contacts.
Egg protein is used in both vaccine types; thus, the vaccine is contraindicated for people who have severe anaphylactic reactions to egg protein.
Adverse effects: A mild, noncommunicable infection occurs in 15% of vaccine recipients. Symptoms appear 7 to 11 days after immunization and include fever, malaise, and a measles-like exanthem. Mumps vaccine has adverse effects only rarely; they include encephalitis (only from a Japanese mumps vaccine strain), seizures, nerve deafness, parotitis, purpura, rash, and pruritus.
Rubella vaccine can cause joint pain, usually in the small peripheral joints 2 to 8 wk after immunization, in < 1% of infants but in ≤ 26% of women. Rash or lymphadenopathy occasionally occurs. The vaccine is not recommended for pregnant women because of the theoretic risk to the fetus. However, inadvertent administration during pregnancy does not necessarily mean a therapeutic abortion is recommended because the actual fetal risk may be nil.
With all of the vaccine formulations, local adverse effects are unusual and include soreness at the injection site.
Adverse effects: Adverse effects are usually mild and include fever, irritability, drowsiness, anorexia, vomiting, and local erythema.
Preparations: Inactivated poliovirus vaccine (IPV) contains a mixture of formalin-inactivated poliovirus types 1, 2, and 3. IPV may contain trace amounts of streptomycin Some Trade Names
No US trade name
Click for Drug Monograph
, neomycin Some Trade Names
NEO-FRADIN
NEO-RX
Click for Drug Monograph
, and polymyxin B Some Trade Names
POLY-RX
. A combination vaccine with IPV, DTaP, and hepatitis B is also available. The live-attenuated oral formulation is no longer available in the US because it causes polio in about 1 of every 2.4 million people who receive the vaccine.
They state:
Adverse effects: No adverse effects have been associated with IPV. Because it may contain trace amounts of neomycin Some Trade Names
NEO-FRADIN
NEO-RX
, streptomycin Some Trade Names
No US trade name
, and polymyxin B Some Trade Names
POLY-RX
, people who are sensitive to any of these drugs may have an allergic reaction to the vaccine.
However this is untrue because other vaccine manufacturer's have stated numerous side-effects in their product information.
Adverse effects: Adverse effects are minimal and include transient pain, tenderness, and redness at the injection site. Occasionally, within 1 mo of vaccination, a mild maculopapular or varicella-like rash develops. Patients who develop this rash should avoid contact with immunocompromised people until it resolves. Spread of the virus from vaccine recipients to susceptible people has been documented in < 1% of recipients but only from those who developed a rash.
Because Reye's syndrome can develop, recipients < 16 yr should avoid salicylates for 6 wk.
Adverse effects: Adverse effects are minimal and include transient pain, tenderness, and redness at the injection site. Occasionally, within 1 mo of vaccination, a mild maculopapular or varicella-like rash develops. Patients who develop this rash should avoid contact with immunocompromised people until it resolves. Spread of the virus from vaccine recipients to susceptible people has been documented in < 1% of recipients but only from those who developed a rash.
Because Reye's syndrome can develop, recipients < 16 yr should avoid salicylates for 6 wk.
Other pages:
This is the text-only version of this page. Click here to see this page with graphics.
Edit this page |
Manage website
Make Your Own Website: 2-Minute-Website.com